Hepatitis B Virus DNA Negativity Acts as a Favorable Prognostic Factor in Hepatocellular Carcinoma Patients |
Li, Xing
(Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University)
Zhong, Xiang (Shenzhen People's Hospital) Chen, Zhan-Hong (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Xing, Yan-Fang (Department of Nephrology, the Third Affiliated Hospital of Guangzhou Medical University) Wu, Dong-Hao (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Chen, Jie (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Ma, Xiao-Kun (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Lin, Qu (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Wen, Jing-Yun (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Wei, Li (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Wang, Tian-Tian (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Ruan, Dan-Yun (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Lin, Ze-Xiao (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Wu, Xiang-Yuan (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Dong, Min (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) |
1 | Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2. DOI ScienceOn |
2 | Eltawil KM, Berry R, Abdolell M, et al (2012). Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre. HPB, 14, 162-70. DOI |
3 | Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al (2011). Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos (t)ide analogues in clinical practice. Hepatology, 53, 1854-63. DOI ScienceOn |
4 | Huang ZL, Luo J, Chen MS, et al (2011). Blood neutrophilto- lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol, 22, 702-9. DOI |
5 | Jang JW, Choi JY, Bae SH, et al (2004). Transarterial chemolipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol, 41, 427-35. DOI ScienceOn |
6 | Jang JW, Choi JY, Bae SH, et al (2006). A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology, 43, 233-40. DOI ScienceOn |
7 | Kim IK, Kim BG, Kim W, et al (2012). Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virusinfected patients undergoing cytotoxic chemotherapy for malignancy. Antimicrob Agents Chemother, 56, 5511-9. DOI |
8 | Lao XM, Luo G, Ye LT, et al (2013). Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver Int, 33, 595-604. DOI |
9 | Lencioni R, Llovet JM (2010). Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis, 30, 52-60. DOI ScienceOn |
10 | Li H, Hu Y, Li N, et al (2012a). Liver fibrosis and five year survival of hepatocellular cancer cases undergoing transcatheter arterial chemo embolization using small doses. Asian Pac J Cancer Prev, 13, 1589-93. 과학기술학회마을 DOI ScienceOn |
11 | Li SH, Guo ZX, Xiao CZ, et al (2013a). Risk factors for early and late intrahepatic recurrence in patients with single hepatocellular carcinoma without macrovascular invasion after curative resection. Asian Pac J Cancer Prev, 14, 4759-63. 과학기술학회마을 DOI ScienceOn |
12 | Li X, Dong M, Lin Q, et al (2013b). Comparison of current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trials. Asia Pac J Clin Oncol, 9, 86-92. DOI |
13 | Li X, Lin Q, Dong M, et al (2010). Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leuk Lymphoma, 51, 1678-85. DOI |
14 | Li X, Xing YF, Lin Q, et al (2012b). The treatment of severe hepatitis B virus reactivation after chemotherapy. Nat Rev Clin Oncol, 9, 350 |
15 | Liver EAftSot (2012). EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 57, 167-85. DOI ScienceOn |
16 | Lok AS, McMahon BJ (2009). Chronic hepatitis B: update 2009. Hepatology, 50, 661-2. DOI ScienceOn |
17 | Torres HA, Davila M (2012). Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol, 9, 156-66. DOI |
18 | Murata S, Mine T, Ueda T, et al (2013). Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma. ScientificWorldJournal, 2013, 479805. |
19 | Nagamatsu H, Itano S, Nagaoka S, et al (2004). Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol, 99, 2369-75. DOI ScienceOn |
20 | Scartozzi M, Faloppi L, Bianconi M, et al (2012). The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. PLoS One, 7, 32653. DOI |
21 | Wang SY, Zhu WH, Vargulick S, et al (2013). Nausea and vomiting after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis. Asian Pac J Cancer Prev, 14, 5995-6000. 과학기술학회마을 DOI ScienceOn |
22 | Wang Y, Chen Y, Ge N, et al (2012). Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization. Ann Surg Oncol, 19, 3540-6. DOI |
23 | Wu XY, Li X, Chen ZH, et al (2013). An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study. Tumour Biol, 34, 909-18. DOI |
24 | Yeo W, Chan HL (2013). Hepatitis B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol, 28, 31-7. DOI |
25 | Yu SJ, Lee JH, Jang ES, et al (2013). Hepatocellular carcinoma: high hepatitis B viral load and mortality in patients treated with transarterial chemoembolization. Radiology, 267, 638-47. DOI |